MediPal Holdings Management

Management criteria checks 2/4

MediPal Holdings' CEO is Shuichi Watanabe, appointed in Apr 2012, has a tenure of 12.58 years. directly owns 0.084% of the company’s shares, worth €2.67M. The average tenure of the management team and the board of directors is 9.9 years and 6.9 years respectively.

Key information

Shuichi Watanabe

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	12.6yrs
CEO ownership	0.08%
Management average tenure	9.9yrs
Board average tenure	6.9yrs

Recent management updates

Recent updates

CEO

Shuichi Watanabe (72 yo)

12.6yrs

Tenure

Mr. Shuichi Watanabe has been Chief Compliance Officer of MediPal Holdings Corporation since June 25, 2020. Mr. Watanabe has been Chief Executive Officer and President at MediPal Holdings Corporation since...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Shuichi Watanabe	Chief Compliance Officer	12.6yrs	no data	0.084% € 2.7m
Yuji Sakon	MD, GM of Administration Division & Director	11.4yrs	no data	0.011% € 350.3k
Toshihide Yoda	Senior MD of Investor Relations	1.4yrs	no data	0.0063% € 198.0k
Yasuhiro Choufuku	Executive VP & Director	8.4yrs	no data	0.025% € 792.2k
Shinjiro Watanabe	GM of Information Systems Management Division & Director	no data	no data	0.017% € 548.3k

9.9yrs

Average Tenure

70yo

Average Age

Experienced Management: 59Z's management team is seasoned and experienced (9.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Shuichi Watanabe	Chief Compliance Officer	24.8yrs	no data	0.084% € 2.7m
Yuji Sakon	MD, GM of Administration Division & Director	12.4yrs	no data	0.011% € 350.3k
Toshihide Yoda	Senior MD of Investor Relations	14.4yrs	no data	0.0063% € 198.0k
Yasuhiro Choufuku	Executive VP & Director	5.4yrs	no data	0.025% € 792.2k
Shinjiro Watanabe	GM of Information Systems Management Division & Director	11.4yrs	no data	0.017% € 548.3k
Kuniko Shoji	Independent Outside Director	6.4yrs	no data	no data
Toshio Asano	Independent Outside Director	7.4yrs	no data	0.0034% € 106.8k
Hiroshi Iwamoto	Independent Outside Director	3.4yrs	no data	no data
Koichi Mimura	Director	4.4yrs	no data	0.00096% € 30.4k
Mitsuko Kagami	Independent Outside Director	10.4yrs	no data	no data
Takuya Yoshida	Director	1.4yrs	no data	0.00048% € 15.2k
Imagawa Kuniaki	Director	2.4yrs	no data	no data

6.9yrs

Average Tenure

66.5yo

Average Age

Experienced Board: 59Z's board of directors are considered experienced (6.9 years average tenure).

MediPal Holdings Management

Management criteria checks 2/4

Key information

Recent management updates

MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024

MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Recent updates

Second quarter 2025 earnings released: EPS: JP¥61.05 (vs JP¥28.08 in 2Q 2024)

Upcoming dividend of JP¥30.00 per share

MediPal Holdings Corporation to Report Q2, 2025 Results on Nov 01, 2024

Dividend of JP¥30.00 announced

Now 25% undervalued after recent price drop

First quarter 2025 earnings released: EPS: JP¥42.95 (vs JP¥52.32 in 1Q 2024)

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

MediPal Holdings Corporation to Report Q1, 2025 Results on Aug 01, 2024

MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744).

Full year 2024 earnings released: EPS: JP¥196 (vs JP¥185 in FY 2023)

MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024

MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 2,500,000 shares, representing 1.19% for ¥5,000 million.

MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion.

Upcoming dividend of JP¥30.00 per share

MediPal Holdings Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Third quarter 2024 earnings released: EPS: JP¥52.80 (vs JP¥59.65 in 3Q 2023)

MediPal Holdings Corporation to Report Q3, 2024 Results on Feb 05, 2024

Second quarter 2024 earnings released: EPS: JP¥28.08 (vs JP¥43.12 in 2Q 2023)

Upcoming dividend of JP¥30.00 per share at 2.3% yield

MediPal Holdings Corporation to Report Q2, 2024 Results on Nov 02, 2023

First quarter 2024 earnings released: EPS: JP¥52.32 (vs JP¥39.39 in 1Q 2023)

MediPal Holdings Corporation to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings released: EPS: JP¥185 (vs JP¥140 in FY 2022)

MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥23.00 per share at 2.6% yield

Third quarter 2023 earnings released: EPS: JP¥59.65 (vs JP¥49.09 in 3Q 2022)

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).

MediPal Holdings Corporation to Report Q3, 2023 Results on Feb 01, 2023

Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022)

Upcoming dividend of JP¥23.00 per share

MediPal Holdings Corporation to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings released: EPS: JP¥39.39 (vs JP¥44.98 in 1Q 2022)

MediPal Holdings Corporation to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings released: EPS: JP¥140 (vs JP¥114 in FY 2021)

MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Upcoming dividend of JP¥21.00 per share

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Now 21% undervalued

Second quarter 2022 earnings released: EPS JP¥43.25 (vs JP¥23.93 in 2Q 2021)

Upcoming dividend of JP¥21.00 per share

First quarter 2022 earnings released: EPS JP¥44.98 (vs JP¥32.88 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥114 (vs JP¥176 in FY 2020)

Upcoming dividend of JP¥21.00 per share

MediPal Holdings Corporation to Report Fiscal Year 2021 Results on May 13, 2021

Third quarter 2021 earnings released: EPS JP¥21.05 (vs JP¥52.72 in 3Q 2020)

Revenue beats expectations

New 90-day high: €16.92

New 90-day high: €16.80

MediPal Holdings Corporation to Report Q3, 2021 Results on Jan 29, 2021

Second quarter 2021 earnings released: EPS JP¥23.93

Revenue misses expectations

First half earnings released

Semi-annual earnings released: Revenue misses expectations

New 90-day low: €15.20

MediPal Holdings Corporation to Report Q2, 2021 Results on Oct 30, 2020

First quarter earnings released

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age